Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
The Body Covers:
The 39th Annual Meeting of the Infectious Diseases Society of America
Moscone Center, San Francisco, California

October 25-28, 2001



The Infectious Diseases Society of America is an organization of physicians, scientists, and other health care professionals dedicated to the promotion and recognition of excellence in infectious disease research, patient care, public health, prevention and education. This year's conference will feature discussions, interactive information sessions, slide presentations and other activities on topics ranging from tuberculosis to HIV resistance testing. Click here for extensive information on what this conference holds in store.

Reporting exclusively for The Body at IDSA 2001 are Douglas T. Dieterich, M.D. and Pablo Tebas, M.D.

Funding for The Body's conference coverage is provided, in part, by unrestricted educational grants from Boehringer-Ingelheim, GlaxoSmithKline and Ortho Biotech.


The Body's Conference Summaries

Pablo Tebas on IDSA

HIV/AIDS: Antiretroviral Therapy (Poster Session 87)

HAART and the Management of HIV-1 Infection: Can Short-Term Changes in the Plasma HIV-1 RNA Level Predict Long-Term Response to Therapy?

Predicting the Unpredictable: The Transmission of Drug-Resistant HIV

Efficacy of Lopinavir (LPV) in Heavily Pretreated Patients

Initiation of Highly Active Antiretroviral Therapy (HAART) at CD4 Level 350: Assessment of Disease Progression, and Drug Failure, Toxicity, and Resistance

Simplification of Protease Inhibitor-Containing HAART Regimen with Abacavir Maintains Viral Suppression and Favorable Adherence in HIV-1 Infected Adults

Retrospective Review of Nevirapine-Induced Hepatotoxicity in HIV/HCV Co-Infected Patients in a Community Health Center

A Retrospective Cohort Study of the Durability of Antiretroviral Therapy Using Nevirapine versus Antiretroviral Therapy Using Protease Inhibitors

Clinical Experience of Amprenavir Following Nelfinavir Use

Final Results of a Pilot, 48-Week Study of Amprenavir/Abacavir/Lamivudine in ART-Naive Subjects with HIV-1 Infection

The Compact Quad, Combivir/Abacavir/Efavirenz -- Preliminary 48-Week Results

Effect of Hepatitis G Co-Infection on Response to Antiretroviral Treatment in HIV-Infected Patients

Once-Weekly Epoetin Alfa Increases Hemoglobin and Improves Quality of Life in Anemic HIV-Positive Patients

Relationship Between Prior Antiretroviral Therapy and Genotypic Testing Among a Large Cohort of HIV-1 Isolates

Ability of Patients with HIV Infection to Predict Changes in Their Own CD4+ Lymphocyte and Viral Load Measurements

HIV/AIDS: Epidemiology/Prevention (Poster Session 88)

Disclosure of HIV Status to Sexual Partners and Association with Condom Use

Cutting-Edge Issues in HIV Medicine (Symposium)

Challenges of Antiretroviral Therapy in the Developing World

Future Horizons in Antiretroviral Drugs

Structured Treatment Interruption: Panacea or Pandora?

HIV and HCV Co-Infection -- Current Status and Future Directions


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement